Our History

More than 90% of the cancer related deaths are attributed to metastasis as well as the development of resistance to existing therapies and tumor relapse. Recently, Cancer Stem Cells (CSCs) are known to be resistant to existing chemotherapies and thus, shown to be responsible for tumor relapse and metastasis. Since there are no drugs available in the market to target CSCs and treat metastasis and tumor relapse, Sathgen is developing drugs, which could work to eliminate cancer stem cell population also will work in combination with existing chemotherapies to eliminate cancer related mortality.

In 2007, Mr. Samir Somaiya from Somaiya group and Dr. Sendurai Mani from MD Anderson Cancer Center jointly started Sathgen Biotech to address this critical need to identify cancer stem cell specific drugs, which would work either alone or in combination with chemotherapies.